$SURG
SurgePays, Inc. Stock $surg

$surg Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032195 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$36.23M	$36.17M	$14.54M
YoY Change	155.92%	148.8%	13.56%
Cost Of Revenue	$29.50M	$34.25M	$12.63M
YoY Change	138.96%	171.08%	12.65%
Gross Profit	$6.724M	$1.921M	$1.903M
YoY Change	271.65%	0.91%	20.02%
Gross Profit Margin	18.56%	5.31%	13.09%
Selling, General & Admin	$2.913M	$2.933M	$2.098M
YoY Change	-21.86%	39.79%	-27.76%
% of Gross Profit	43.32%	152.71%	110.23%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$268.9K	$140.3K	$181.1K
YoY Change	49.35%	-22.53%	-40.94%
% of Gross Profit	4.0%	7.31%	9.52%
Operating Expenses	$3.180M	$2.933M	$2.279M
YoY Change	-18.63%	28.68%	-29.01%
Operating Profit	$3.544M	-$1.012M	-$375.9K
YoY Change	-268.85%	169.33%	-76.87%
Interest Expense	-$520.1K	-$686.0K	-$1.418M
YoY Change	-147.63%	-51.64%	61.72%
% of Operating Profit	-14.68%
Other Income/Expense, Net	$316.3K	-$744.0K	$0.00
YoY Change	-105.0%
Pretax Income	$3.340M	-$1.756M	-$1.658M
YoY Change	-148.8%	5.94%	-33.74%
Income Tax
% Of Pretax Income
Net Earnings	$3.045M	-$1.540M	-$1.658M
YoY Change	-144.49%	-7.1%	-33.74%
Net Earnings / Revenue	8.4%	-4.26%	-11.4%
Basic Earnings Per Share		-$0.12	-$0.51
Diluted Earnings Per Share	$0.24	-$123.8K	-$507.9K
COMMON SHARES
Basic Shares Outstanding	12.53M shares	12.41M shares	3.264M shares
Diluted Shares Outstanding		12.44M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.036M	$7.892M	$635.5K
YoY Change	11.97%	1141.81%	50.84%
Cash & Equivalents	$7.036M	$7.892M	$635.5K
Short-Term Investments
Other Short-Term Assets	$111.5K	$131.9K	$35.00K
YoY Change		276.71%	-86.62%
Inventory	$11.19M	$9.492M	$502.1K
Prepaid Expenses	$111.5K	$131.9K
Receivables	$9.230M	$9.467M	$1.668M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.56M	$26.98M	$2.840M
YoY Change	98.41%	850.04%	137.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$643.4K	$747.1K	$739.1K
YoY Change	220.97%	1.07%	10.44%
Goodwill	$1.667M	$1.667M
YoY Change	92.3%
Intangibles	$2.780M	$2.943M
YoY Change	-19.03%
Long-Term Investments	$354.2K	$401.2K	$411.1K
YoY Change	-20.1%	-2.4%	-9.99%
Other Assets
YoY Change
Total Long-Term Assets	$6.440M	$6.377M	$5.791M
YoY Change	14.84%	10.13%	-10.37%
TOTAL ASSETS
Total Short-Term Assets	$27.56M	$26.98M	$2.840M
Total Long-Term Assets	$6.440M	$6.377M	$5.791M
Total Assets	$34.00M	$33.36M	$8.631M
YoY Change	74.38%	286.53%	12.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.513M	$17.23M	$6.453M
YoY Change	-6.0%	166.98%	279.63%
Accrued Expenses	$39.49K	$38.61K	$68.30K
YoY Change	-19.98%	-43.47%	36.19%
Deferred Revenue
YoY Change
Short-Term Debt	$2.650M	$7.766M	$2.919M
YoY Change	57.73%	166.07%	219.74%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.46M	$26.93M	$11.24M
YoY Change	134.68%	139.52%	-6.07%
LONG-TERM LIABILITIES
Long-Term Debt	$5.022M	$5.557M	$7.486M
YoY Change	-8.89%	-25.78%	122.81%
Other Long-Term Liabilities	$399.4K	$409.7K	$447.0K
YoY Change	-9.0%	-8.35%	-63.82%
Total Long-Term Liabilities	$5.421M	$5.966M	$7.933M
YoY Change	-8.9%	-24.79%	72.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.46M	$26.93M	$11.24M
Total Long-Term Liabilities	$5.421M	$5.966M	$7.933M
Total Liabilities	$28.89M	$32.90M	$19.18M
YoY Change	81.11%	71.54%	15.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.80M	-$38.85M
YoY Change	1.94%
Common Stock	$14.12K	$12.50K
YoY Change	17.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.991M	$631.8K	-$10.55M
YoY Change
Total Liabilities & Shareholders Equity	$34.00M	$33.36M	$8.631M
YoY Change	74.38%	286.53%	12.71%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	$3.045M	-$1.540M	-$1.658M
YoY Change	-144.49%	-7.1%	-33.74%
Depreciation, Depletion And Amortization	$268.9K	$140.3K	$181.1K
YoY Change	49.35%	-22.53%	-40.94%
Cash From Operating Activities	$4.744M	-$803.0K	-$2.289M
YoY Change	-158.26%	-64.92%	99.64%
INVESTING ACTIVITIES
Capital Expenditures	$1.790K	$1.790K	-$5.420K
YoY Change	-18000.0%	-133.03%	313.74%
Acquisitions
YoY Change
Other Investing Activities	-$387.2K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$389.0K	$1.790K	-$5.410K
YoY Change	3889600.0%	-133.09%	-139.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.212M	-11.29K	2.355M
YoY Change	-137.79%	-100.48%	93.93%
NET CHANGE
Cash From Operating Activities	4.744M	-803.0K	-2.289M
Cash From Investing Activities	-389.0K	1.790K	-5.410K
Cash From Financing Activities	-5.212M	-11.29K	2.355M
Net Change In Cash	-856.4K	-812.5K	60.70K
YoY Change	-115.16%	-1438.5%	-25.54%
FREE CASH FLOW
Cash From Operating Activities	$4.744M	-$803.0K	-$2.289M
Capital Expenditures	$1.790K	$1.790K	-$5.420K
Free Cash Flow	$4.743M	-$804.8K	-$2.284M
YoY Change	-158.23%	-64.76%	99.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2022Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2021Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001392694
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2021Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2022Q3	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment		usd
CY2021Q3	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment		usd
	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment		usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q2	SURG	Stock Issued During Period Value New Issues Stock Issued As Direct Offering Costs StockIssuedDuringPeriodValueNewIssuesStockIssuedAsDirectOfferingCosts		usd
CY2022Q3	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2021Q3	SURG	Adjustments To Additional Paid In Capital Stock True Up Adjustment Related To Initial Acquisition Of True Wireless AdjustmentsToAdditionalPaidInCapitalStockTrueUpAdjustmentRelatedToInitialAcquisitionOfTrueWireless		usd
CY2021Q3	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	SURG	Warrants Issued For Interest Expense WarrantsIssuedForInterestExpense		usd
	SURG	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		usd
	SURG	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan		usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	SURG	Proceeds From Short Term Debt Excluding Notes Payable ProceedsFromShortTermDebtExcludingNotesPayable		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1		usd
	SURG	Debt Discountissue Costs Recorded In Connection With Debtderivative Liabilities DebtDiscountissueCostsRecordedInConnectionWithDebtderivativeLiabilities		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	SURG	Conversion Of Debt Into Equity ConversionOfDebtIntoEquity		usd
	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability		usd
	SURG	Termination Of Ecs Rou Lease TerminationOfEcsRouLease		usd
	SURG	Stock Issued In Connection With Debt Modification StockIssuedInConnectionWithDebtModification		usd
	SURG	Shares Issued Under Makewhole Arrangement SharesIssuedUnderMakewholeArrangement		usd
	SURG	Stock Issued For Acquisition Of Membership Interest In Ecs StockIssuedForAcquisitionOfMembershipInterestInEcs		usd
	SURG	Deconsolidation Of Subsidiary True Wireless DeconsolidationOfSubsidiaryTrueWireless		usd
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber		shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2020Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested And Non Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvestedAndNonExercisable		usd
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2022Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested And Non Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvestedAndNonExercisable		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40992
	dei	Entity Registrant Name EntityRegistrantName	SURGEPAYS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0550352
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3124 Brother Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 104
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bartlett
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	38133
	dei	City Area Code CityAreaCode	901
	dei	Local Phone Number LocalPhoneNumber	302-9587
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12530928	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7892050	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6283496	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9467422	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3249889	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	9492385	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4359296	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	131853	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	26983710	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	13892681	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	747056	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	200448	usd
CY2022Q3	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2943353	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3433484	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1666782	usd
CY2021Q4	us-gaap	Goodwill Goodwill	866782	usd
CY2022Q3	us-gaap	Investments Investments	401190	usd
CY2021Q4	us-gaap	Investments Investments	443288	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	441921	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	486668	usd
CY2022Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	5630097	usd
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	5407073	usd
CY2022Q3	us-gaap	Assets Assets	33360863	usd
CY2021Q4	us-gaap	Assets Assets	19500202	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13671092	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6602577	usd
CY2022Q3	SURG	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	3558258	usd
CY2021Q4	SURG	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	1389798	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1896510	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	276250	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38606	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49352	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1086413	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1553799	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	126418	usd
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	6679597	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26930476	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9998194	usd
CY2022Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	4974403	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	4507017	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	582226	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1004767	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	409672	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	438903	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5966301	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5950687	usd
CY2022Q3	us-gaap	Liabilities Liabilities	32896777	usd
CY2021Q4	us-gaap	Liabilities Liabilities	15948881	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12348834	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12348834	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12063834	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12063834	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	12496	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12064	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39467956	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38662340	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38848912	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35123343	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	631800	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3551321	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-167714	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	464086	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33360863	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19500202	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36171345	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14538353	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85317860	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36905373	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	34250541	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	12634871	usd
	us-gaap	Cost Of Revenue CostOfRevenue	78572421	usd
	us-gaap	Cost Of Revenue CostOfRevenue	32544619	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2933204	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2909954	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9655529	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10262479	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	37183745	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	15544825	usd
	us-gaap	Costs And Expenses CostsAndExpenses	88227950	usd
	us-gaap	Costs And Expenses CostsAndExpenses	42807098	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1012400	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1006472	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2910090	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5901725	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	633593	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	1236778	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1370236	usd
	us-gaap	Interest Expense Other InterestExpenseOther	4637236	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1775057	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-202784	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	746896	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-52435	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	21072	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-42099	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3556	usd
CY2021Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	136487	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	979469	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	1895871	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	57933	usd
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-630580	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	95001	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-2008036	usd
	SURG	Gain On Forgiveness Of Ppp Loan Government GainOnForgivenessOfPppLoanGovernment	524143	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-743961	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-651423	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-983193	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-785577	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1756361	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1657895	usd
	us-gaap	Profit Loss ProfitLoss	-3893283	usd
	us-gaap	Profit Loss ProfitLoss	-6687302	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-216163	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-167714	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1540198	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1657895	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3725569	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6687302	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12443052	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3264274	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12259907	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3024487	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	38953	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32645	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1212334	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2354589	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	411400	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	76451	usd
CY2022Q2	SURG	Adjustments To Additional Paid In Capital Warrant Issued Warrants Issued As Interest Expense AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWarrantsIssuedAsInterestExpense	212608	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	81094	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-973037	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2172399	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2022Q3	SURG	Adjustments To Additional Paid In Capital Warrant Issued Warrants Issued As Interest Expense AdjustmentsToAdditionalPaidInCapitalWarrantIssuedWarrantsIssuedAsInterestExpense	38754	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-216163	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1540198	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	464086	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10725966	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	61571	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1510000	usd
CY2021Q1	SURG	Stock And Warrants Issued With Debt Recorded As Debt Discount StockAndWarrantsIssuedWithDebtRecordedAsDebtDiscount	2038635	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	858158	usd
CY2021Q1	SURG	Stock Issued Under Makewhole Arrangements StockIssuedUnderMakewholeArrangements	90401	usd
CY2021Q1	SURG	Stock Issued In Connection With Debt Modifications StockIssuedInConnectionWithDebtModifications	108931	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	464713	usd
CY2021Q1	SURG	Stock Issued During Period Value For Acquisition Of Membership Interest StockIssuedDuringPeriodValueForAcquisitionOfMembershipInterest	17900	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815431	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10391088	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10269	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-26741	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1290437	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-213976	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9331099	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9331099	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	56825	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-93483	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	124635	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	124635	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	89844	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	89844	usd
	SURG	Warrants Issued For Interest Expense WarrantsIssuedForInterestExpense	251362	usd
	SURG	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	746896	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1657895	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10545905	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10545905	usd
	us-gaap	Profit Loss ProfitLoss	-3893283	usd
	us-gaap	Profit Loss ProfitLoss	-6687302	usd
	us-gaap	Inventory Write Down InventoryWriteDown	51718	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	664534	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	579372	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	44747	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	122681	usd
	SURG	Amortization Of Debt Discount AmortizationOfDebtDiscount	-95001	usd
	SURG	Amortization Of Debt Discount AmortizationOfDebtDiscount	-2008036	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27882	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8411	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1775057	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	935375	usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-42098	usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-3556	usd
	SURG	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan	524143	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	1895871	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6217533	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1487131	usd
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-105532	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5184807	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	398450	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	131853	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-32062	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7074491	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	166193	usd
	SURG	Increase Decrease In Accounts Payable And Accrued Liabilities Related Party IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty	2168460	usd
	SURG	Increase Decrease In Accounts Payable And Accrued Liabilities Related Party IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty	540089	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1620260	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-207800	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39977	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-126533	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3951043	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7144369	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9611	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51396	usd
	us-gaap	Payments For Software PaymentsForSoftware	300000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	800000	usd
	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	325316	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1109611	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-376712	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1510000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3688000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	163000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6700000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	853386	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	250000	usd
	SURG	Proceeds From Short Term Debt Excluding Notes Payable ProceedsFromShortTermDebtExcludingNotesPayable	518167	usd
	SURG	Repayments Of Short Term Debt Excluding Notes Payable RepaymentsOfShortTermDebtExcludingNotesPayable	30792	usd
	SURG	Repayments Of Short Term Debt Excluding Notes Payable RepaymentsOfShortTermDebtExcludingNotesPayable	3425	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2550000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1220515	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6669208	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7482613	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1608554	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38468	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6283496	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	673995	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7892050	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	635527	usd
	us-gaap	Interest Paid Net InterestPaidNet	195950	usd
	us-gaap	Interest Paid Net InterestPaidNet	117836	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	115404	usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	411400	usd
	SURG	Debt Discountissue Costs Recorded In Connection With Debtderivative Liabilities DebtDiscountissueCostsRecordedInConnectionWithDebtderivativeLiabilities	-2406097	usd
	us-gaap	Stock Issued1 StockIssued1	1879785	usd
	SURG	Conversion Of Debt Into Equity ConversionOfDebtIntoEquity	948002	usd
	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability	515848	usd
	SURG	Termination Of Ecs Rou Lease TerminationOfEcsRouLease	228752	usd
	SURG	Stock Issued In Connection With Debt Modification StockIssuedInConnectionWithDebtModification	108931	usd
	SURG	Shares Issued Under Makewhole Arrangement SharesIssuedUnderMakewholeArrangement	90401	usd
	SURG	Stock Issued For Acquisition Of Membership Interest In Ecs StockIssuedForAcquisitionOfMembershipInterestInEcs	17900	usd
	SURG	Deconsolidation Of Subsidiary True Wireless DeconsolidationOfSubsidiaryTrueWireless	2434552	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3725569	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3951043	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38848912	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	464086	usd
	SURG	Working Capital Deficit WorkingCapitalDeficit	53234	usd
CY2022Q3	us-gaap	Cash Cash	7892050	usd
	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	100	usd
	SURG	Reimbursement Cost Per Customer ReimbursementCostPerCustomer	30	usd
CY2022Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	584038	usd
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	905281	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1666782	usd
CY2021Q4	us-gaap	Goodwill Goodwill	866782	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	SURG	Notes Receivable Gross Due Remainder Of Fiscal Year NotesReceivableGrossDueRemainderOfFiscalYear	52227	usd
CY2022Q3	SURG	Notes Receivable Gross Due In Next Twelve Months NotesReceivableGrossDueInNextTwelveMonths	89532	usd
CY2022Q3	SURG	Notes Receivable Gross Due In Year Two NotesReceivableGrossDueInYearTwo	44766	usd
CY2022Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	186525	usd
CY2022Q3	SURG	Less Interest Receivable LessInterestReceivable	9674	usd
CY2022Q3	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2021Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	1895871	usd
CY2021Q2	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2021Q2	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	176851	usd
CY2021Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	325316	usd
CY2021Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	74650	usd
CY2021Q2	us-gaap	Disposal Group Including Discontinued Operation Inventory1 DisposalGroupIncludingDiscontinuedOperationInventory1	107089	usd
CY2021Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	20645	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10981	usd
CY2021Q2	SURG	Sale Of Assets SaleOfAssets	538681	usd
CY2021Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities	1183850	usd
CY2021Q2	SURG	Disposal Group Including Discontinued Operation Line Of Credit DisposalGroupIncludingDiscontinuedOperationLineOfCredit	912870	usd
CY2021Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	150000	usd
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	10981	usd
CY2021Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	2257701	usd
CY2021Q2	SURG	Liabilities Net Assumed LiabilitiesNetAssumed	1719020	usd
CY2021Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	1895871	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_z4BT0PNCSxj8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0dxP6F6Kauh">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the nine months ended September 30, 2022 and the year ended December 31, 2021, respectively, include, allowance for doubtful accounts and other receivables, inventory reserves and classifications, valuation of loss contingencies, valuation of derivative liabilities, valuation of stock-based compensation, estimated useful lives related to intangible assets and property and equipment, implicit interest rate in right-of-use operating leases, uncertain tax positions, and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	137218	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	137218	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	51718	usd
	us-gaap	Inventory Write Down InventoryWriteDown	51718	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	9492385	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4359296	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021Q3	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84C_eus-gaap--DerivativesReportingOfDerivativeActivity_zS3upOyd5Xn7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfY2MKQP14Q1">Derivative Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), “<i>Distinguishing Liabilities from Equity”</i> and FASB ASC Topic No. 815, (“ASC 815”) “<i>Derivatives and Hedging”</i>. Derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. The Company uses a binomial model to determine fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SURGEPAYS, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEPTEMBER 30, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon conversion of a note for shares of common stock where the embedded conversion option has been bifurcated and accounted for as a derivative liability, the Company records the shares at fair value, relieves all related notes, derivatives, and debt discounts, and recognizes a net gain or loss on debt extinguishment. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q3	SURG	Percentage Of Total Revenues PercentageOfTotalRevenues	1	pure
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1896510	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	276250	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85317860	usd
CY2022Q3	SURG	Percentage Of Total Revenues PercentageOfTotalRevenues	1	pure
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36905373	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022Q3	us-gaap	Investments Investments	401190	usd
CY2021Q4	us-gaap	Investments Investments	443288	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-52435	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	21072	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-42099	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3556	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	429010	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	34708	usd
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	76413	usd
	us-gaap	Advertising Expense AdvertisingExpense	170714	usd
	us-gaap	Advertising Expense AdvertisingExpense	638706	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5681364	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4651206	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	6914425	usd
CY2022Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	6914425	usd
CY2021Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	423940	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	14320854	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1113393	usd
CY2022Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	6914425	usd
CY2021Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	423940	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	14320854	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1113393	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zlXPn63WOkP" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zEUlN4KEjixj">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ equity (deficit), or cash flows.</span></p>
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1005946	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	283484	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	83092	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	366236	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	341982	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	165788	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	747056	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	200448	usd
CY2022Q3	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	711400	usd
	us-gaap	Payments For Software PaymentsForSoftware	300000	usd
CY2022Q2	us-gaap	Payments For Software PaymentsForSoftware	100000	usd
CY2022Q3	us-gaap	Payments For Software PaymentsForSoftware	200000	usd
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	85000	shares
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	411400	usd
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.84
CY2022Q3	us-gaap	Depreciation Depreciation	140318	usd
CY2021Q3	us-gaap	Depreciation Depreciation	17756	usd
	us-gaap	Depreciation Depreciation	174403	usd
	us-gaap	Depreciation Depreciation	50491	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2810167	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2320036	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2943353	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3433484	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	490131	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	528881	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	163377	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	653508	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	653508	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	653508	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	653508	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	165944	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2943353	usd
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	377743	usd
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	524143	usd
	SURG	Debt Instrument Issuance Date Of Notes DebtInstrumentIssuanceDateOfNotes	2021
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12000	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
	us-gaap	Interest Expense InterestExpense	400000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	100000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1101000	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	101000	usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	341986	usd
CY2022Q3	us-gaap	Secured Debt SecuredDebt	5000000	usd
CY2021Q4	us-gaap	Secured Debt SecuredDebt	0	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2550000	usd
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	1000000	usd
CY2021Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.06	pure
CY2021Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	0	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-202784	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	746896	usd
CY2022Q3	SURG	Derivative Expense DerivativeExpense	0	usd
CY2021Q3	SURG	Derivative Expense DerivativeExpense	0	usd
	SURG	Derivative Expense DerivativeExpense	0	usd
	SURG	Derivative Expense DerivativeExpense	1775057	usd
CY2022Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	0	usd
CY2021Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	136487	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	0	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	979469	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	44747	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	140464	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	17216	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	31898	usd
	us-gaap	Lease Cost LeaseCost	61963	usd
	us-gaap	Lease Cost LeaseCost	172362	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	441921	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	486668	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38606	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49352	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	409672	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	438903	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	448278	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	488255	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	39977	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	117357	usd
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M8D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	39977	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	117357	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	515848	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	515848	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M26D
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	14878	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	60294	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	61876	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	63460	usd
CY2022Q3	SURG	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	351356	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	551864	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	103586	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	448278	usd
CY2016Q3	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss ContractWithCustomerReceivableBeforeAllowanceForCreditLoss	1500000	usd
CY2016Q3	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss ContractWithCustomerReceivableBeforeAllowanceForCreditLoss	2500000	usd
CY2022Q1	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	450000	usd
CY2022Q1	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	100000000000	usd
CY2022Q1	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	3650000	usd
CY2022Q1	us-gaap	Escrow Deposit EscrowDeposit	375000	usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	3750000	usd
CY2021Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	73000.00	usd
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 50 reverse stock split of all classes of its stock
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Voting at 1 vote per share
CY2022Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	200000	shares
CY2022Q2	SURG	Net Effect On Stockholders Deficit NetEffectOnStockholdersDeficit	0	usd
CY2022Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	711400	usd
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	300000	usd
CY2022Q2	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	100000	usd
CY2022Q3	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	200000	usd
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	13411	shares
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	99436	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3562829	usd
CY2021	SURG	Stock And Warrants Issued With Debt Recorded As Debt Discount StockAndWarrantsIssuedWithDebtRecordedAsDebtDiscount	2645890	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	102194	usd
CY2021Q4	SURG	Derivative Fair Value Of Derivative Liability Aggregate Discount DerivativeFairValueOfDerivativeLiabilityAggregateDiscount	2748084	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M28D
CY2020Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	17004	shares
CY2020Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2020	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P6Y1M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3401	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P5Y1M28D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	13603	shares
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P5Y1M28D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M1D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6801	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y5M1D
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	10202	shares
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P4Y5M1D
CY2022Q3	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	9294	usd
CY2021Q3	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	9294	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	27882	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	27882	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	52663	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y5M1D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	194317	shares
CY2020Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	32.50
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y6M7D
CY2020Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	194317	shares
CY2020Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	32.50
CY2020	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y6M7D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5935450	shares
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted	8.01
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2133	shares
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	12.50
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	44650	shares
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	23.49
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6082984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	8.68
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y11M4D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5852984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	8.70
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P2Y10M6D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested	230000	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested	8.00
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested	P4Y10M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	153000	shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted	4.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	498750	shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	8.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	88671	shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	40.04
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5648563	shares
CY2022Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	8.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
CY2022Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5648563	shares
CY2022Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	8.14
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P2Y1M6D
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested	P0Y
CY2022Q2	us-gaap	Notes Issued1 NotesIssued1	1700000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	51000	shares
CY2022Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	115404	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	78992	shares
CY2022Q3	SURG	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	268750	shares
CY2021Q4	SURG	Number Of Warrants Sold For Cash NumberOfWarrantsSoldForCash	5290000	shares
CY2021Q4	SURG	Number Of Warrants Repriced NumberOfWarrantsRepriced	433017	shares
CY2021	SURG	Warrant Modification Expense WarrantModificationExpense	74476	usd
CY2022Q3	us-gaap	Revenues Revenues	36171345	usd
CY2021Q3	us-gaap	Revenues Revenues	14538353	usd
	us-gaap	Revenues Revenues	85317860	usd
	us-gaap	Revenues Revenues	36905373	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	34250541	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	12634871	usd
	us-gaap	Cost Of Revenue CostOfRevenue	78572421	usd
	us-gaap	Cost Of Revenue CostOfRevenue	32544619	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2933204	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2909954	usd
	us-gaap	Operating Expenses OperatingExpenses	9655529	usd
	us-gaap	Operating Expenses OperatingExpenses	10262479	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1012400	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1006472	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2910090	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5901725	usd
CY2022Q3	us-gaap	Assets Assets	33360863	usd
CY2021Q4	us-gaap	Assets Assets	19500202	usd
CY2022Q3	us-gaap	Liabilities Liabilities	32896777	usd
CY2021Q4	us-gaap	Liabilities Liabilities	15948881	usd

Files In Submission

Name	View Source	Status
0001493152-22-032195-index-headers.html	Edgar Link	pending
0001493152-22-032195-index.html	Edgar Link	pending
0001493152-22-032195.txt	Edgar Link	pending
0001493152-22-032195-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
surg-20220930.xsd	Edgar Link	pending
surg-20220930_def.xml	Edgar Link	unprocessable
surg-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
surg-20220930_cal.xml	Edgar Link	unprocessable
surg-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SURG
SurgePays, Inc. Stock $surg

2022 Q4 Form 10-Q Financial Statement

#000149315222032195 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG SurgePays, Inc. Stock $surg

2022 Q4 Form 10-Q Financial Statement

#000149315222032195 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG
SurgePays, Inc. Stock $surg